Intranasal Drug And Vaccine Delivery Market Size, Share & Trends Analysis Report By Product, By Dosage (Deep Learning, Machine Learning), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Intranasal Drug And Vaccine Delivery Market Size, Share & Trends Analysis Report By Product, By Dosage (Deep Learning, Machine Learning), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Intranasal Drug And Vaccine Delivery Market Growth & Trends

The global intranasal drug and vaccine delivery market size is estimated to reach USD 103.33 billion by 2030, registering to grow at a CAGR of 6.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing preference for nasal products over parenteral and oral formulations for instant relief is one of the major factors driving the market.

Increasing demand and advancements in technology are some of the major market drivers. Rising investment in research and development has escalated the clinical trial programs indicated for the treatment of various conditions. In March 2020, Auris Medical Holding Ltd. provided the Phase 2 trial update for intranasal betahistine (AM-125) for the treatment of acute peripheral vertigo.

Increasing prevalence of chronic respiratory disorders augments the demand for intranasal drug and vaccine devices as they are commonly prescribed by medical professionals owing to the easy self-administration technique. According to the Centers for Disease Control and Prevention (CDC), in 2019, 1 in 13 people have asthma, with more than 25 million Americans living with asthma. CDC also stated that asthma accounted for an estimated 14.2 million hospital visits, 439,000 hospital discharges, and 1.8 million emergency department visits annually.

Liquid delivery devices dominated the market in 2019 on account of their availability in various formulations, including aqueous solutions, emulsions, and suspensions. The unit-does segment is anticipated to witness lucrative growth due to increasing approvals for the treatment of various disorders. Moreover, majority of the vaccine formulations under development are unit-dose formulations as single intranasal vaccine dose is commonly recommended by medical professionals.

Asia Pacific is expected to emerge as the fastest growing regional market over the forecast period. This is primarily attributed to increasing product development protocols, economic growth, and increase in the number of local market players involved in the development of novel drug delivery systems.

Intranasal Drug And Vaccine Delivery Market Report Highlights

• Liquid delivery devices dominated the market with a revenue share of 43.7% in 2024. These devices, including metered spray pumps, circumvent first-pass metabolism, enhancing bioavailability and accelerating therapeutic effects.
• Multi-dose systems led the market with a revenue share of 64.1% in 2024. Multi-dose systems provide improved tolerance and convenience, enabling patients to self-administer medications with fewer refills.
• Respiratory disorders held the largest market share of 41.1% in 2024, owing to the efficacy of intranasal delivery for conditions such as asthma, COPD, and allergic rhinitis.
• Retail pharmacies dominated the market and accounted for a share of 45.1% in 2024, fueled by rising patient awareness and a growing trend towards self-administration of medications.

Please note The report will be delivered in 2-3 business days upon order notification.